A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours

Trial Profile

A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs VAL 201 (Primary)
  • Indications Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors ValiRx
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 04 Jan 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top